– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – Results demonstrate olezarsen may represent a novel treatment option for this rare,
The post Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome appeared first on Ionis Pharmaceuticals, Inc..